
ASND
Ascendis Pharma A/S
$220.48
$0.00(0.00%)
40
Overall
--
Value
40
Tech
--
Quality
Market Cap
$14.18B
Volume
486.74K
52W Range
$124.06 - $248.60
Target Price
$290.12
Company Overview
| Mkt Cap | $14.18B | Price | $220.48 |
| Volume | 486.74K | Change | +0.00% |
| P/E Ratio | -37.5 | Open | $225.00 |
| Revenue | $363.6M | Prev Close | $220.48 |
| Net Income | $-378.1M | 52W Range | $124.06 - $248.60 |
| Div Yield | N/A | Target | $290.12 |
| Overall | 40 | Value | -- |
| Quality | -- | Technical | 40 |
No chart data available
About Ascendis Pharma A/S
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing TransCon-based therapies for unmet medical needs in Denmark, rest of Europe, North America, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It also develops a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. Ascendis Pharma A/S was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Sector: Healthcare
Industry: Biotechnology
Latest News
Analysts Are Bullish on Top Healthcare Stocks: Ascendis Pharma (ASND), Encompass Health (EHC)
Catie Powers•2 days ago
Ascendis Pharma Expands Share Capital Following March 30 Warrant Exercises
TipRanks Auto-Generated Newsdesk•9 days ago
Ascendis Pharma Shareholders Back Board, Loss Carryforward and New Buyback Mandate at 2026 AGM
TipRanks Auto-Generated Newsdesk•15 days ago
Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT) and Ascendis Pharma (ASND)
Brian Anderson•22 days ago
Analysts Offer Insights on Healthcare Companies: Cogent Biosciences (COGT) and Ascendis Pharma (ASND)
Brian Anderson•22 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | ASND | $220.48 | 0% | 486.74K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |